Abstract This study was aimed at evaluating whether the nitric oxide (NO)/cyclic GMP (cGMP) signaling pathway is altered in platelets from patients with an acute coronary syndrome (unstable angina and acute myocardial infarction). We investigated 10 patients with unstable angina (UA), 14 with acute myocardial infarction (AMI) and 14 age and sexmatched healthy subjects. The serum markers of platelet activation (sP-selectin), inflammation (TNF-a and erythrocyte sedimentation rate), thrombotic state (fibrinogen) and plaque disruption were significantly higher in both UA and AMI patients compared to the healthy controls. In their platelets we assessed the cGMP levels in basal conditions and after stimulation with sodium nitroprusside (SNP), and performed Western blot analysis of homogenates to measure the expression of soluble guanylate cyclase isoforms. Basal levels of cGMP (pmol/10 10 platelets) were significantly higher in platelets from UA patients (1,097 ± 111; p \ 0.0001) and AMI (1,122 ± 77; p \ 0.0001) compared to those collected from healthy controls (497 ± 80). The platelets of AMI patients exhibited a lack of cGMP increase after SNP stimulation in comparison with UA patients. The phosphorylation of upstream (Akt1 protein kinase a and endothelial NO synthase) and downstream (vasodilatorstimulated phosphoprotein, VASP) signaling proteins of the NO/cGMP pathway was investigated: serine phosphorylation in Akt1, eNOS and VASP was enhanced in platelets from UA and AMI patients when compared to controls. Furthermore, in AMI patients the inhibitors of guanylate cyclase and cGMP-dependent protein kinase did not revert the VASP phosphorylation. These data suggest that platelets from AMI patients are more resistant to SNP stimulation, not only as cGMP production, but also in terms of VASP activation. From these ex vivo results we hypothesize that the increased inflammatory state which often accompanies patients with cardiovascular diseases might promote a platelet preactivation resulting in their reduced sensitivity to NO.
Introduction
Nitric oxide (NO) is an important modulator of both vasomotor tone and platelet function, leading to vasodilation and inhibition of platelet aggregation and adhesion [11, 32] . NO acts by stimulating soluble guanylate cyclase (sGC) to increase cyclic guanosine 3 0 ,5 0 -monophosphate (cGMP) synthesis and consequently modulate several effectors, such as cGMP-dependent protein kinase (PKG), cGMP-dependent ion channels and cGMP-regulated phosphodiesterases [25, 28] . Chronic as well as acute coronary heart disease has been associated with increased platelet aggregability. Unstable angina (UA) and acute myocardial infarction (AMI) are conditions associated with increased platelet aggregability, measured as decreased platelet responsiveness to the antiaggregatory effects of NO donors, such as nitroglycerin and sodium nitroprusside (SNP) [4, 14, 23] . The molecular mechanism of this NO resistance remains to be elucidated. Although NO, by elevating intracellular cGMP, is known to inhibit platelet activation [20] , it has been recently demonstrated that the major NO synthase (NOS) isoform expressed in platelets, the endothelial NOS (eNOS), may play a stimulatory role in low-dose agonist-induced platelet activation and promote an in vivo thrombotic response in an injury-induced arterial thrombosis model [17, 19] . Additional evidence indicates that low concentrations of NO promote a discrete platelet degranulation [27] . Such stimulatory role of eNOS seems to be dependent on cGMP elevation caused by NOmediated sGC activation, promoting the aggregationdependent platelet secretion of granules contents [17, 19] . This suggests the possibility that NO may play a biphasic role in platelet activation: low concentrations, such as those produced by platelet eNOS, could promote, while high concentrations could inhibit platelet activation [17, 19] .
The present study aims at clarifying whether the NO/ cGMP signaling pathway, investigated in terms of phosphorylation of upstream (Akt and eNOS) and downstream (VASP) signaling proteins may disclose specific response patterns in platelets from patients with acute coronary syndrome compared to control subjects.
Materials and methods

Study population
The study population included 24 unrelated patients consecutively admitted at the Emergency Department with a diagnosis of acute coronary syndrome as a first manifestation of coronary artery disease. For inclusion in the study the chest pain onset had to be within 8 h from the admission. The endorsed exclusion criteria were: known history of coronary heart disease; previous coronary revascularizations; malignant hypertension; aortic stenosis; hypertrophic cardiomyopathy; anemia; hypovolemia; nitrates assumption; chronic therapy with salicylates (or similar compounds), statins or other antiplatelet and anticoagulant drugs; altered values of circulating platelets and coagulation factors; chronic inflammatory diseases; chronic steroid treatment (in the last 15 days from admission); surgical procedures or major trauma within the last month.
Ten patients presented with UA and 14 with AMI (defined on the Joint European Society of Cardiology/ American Heart Association guidelines) [30] . The control group was constituted of 14 healthy subjects, matched for age and sex, not presenting clinical evidence of coronary heart disease. All subjects gave written informed consent for participation in the study, which was approved by the institutional ethic committee and performed according to the principles of the latest update of the Helsinki Declaration.
Laboratory testing
Platelet count, erythrocyte sedimentation rate, fibrinogen and high sensitivity C-reacting protein were performed on blood samples collected with free-fall technique to avoid aggregation by local stasis, in one-tenth volume of 3.8% trisodium citrate and centrifuged for 10 min at 3,000 rpm. Venipuncture was performed in the Emergency Department before any drug administration (aspirin, nitrates or anticoagulants). Measurements were performed by conventional clinical chemistry methods.
Measurement of serum soluble selectin-P and tumor necrosis factor-a Levels of serum soluble selectin-P (sP-selectin) and tumor necrosis factor-a (TNF-a) were measured, respectively, with the human sP-selectin ELISA Kit (R&D Systems, Minneapolis, MN, USA) and the human TNF-a ELISA Kit (Endogen, Pierce Biotechnology, Rockford, USA).
Materials
Plasticware was purchased from Falcon (Becton-Dickinson, Franklin Lakes, NJ, USA). Tris buffer saline (TBS) 109 was composed as follows: 25 mM Tris base, 0.2 M glycine, 20% methanol, pH 8.5. The electrophoresis reagents were produced by Bio-Rad Laboratories (Richmond, CA, USA). The protein contents of platelet-rich plasma (PRP) were assessed with the BCA kit from Pierce (Rockford, IL, USA). Unless otherwise specified, reagents were purchased from Sigma-Aldrich (Milano, Italy).
Measurement of platelet cGMP
The measurement of platelet cGMP was performed, as detailed elsewhere, [4] in the absence or presence of SNP (12.5 lM).
Western blot analysis
In VASP experiments, aliquots of PRP from the three population groups were pre-treated for 15 min at 37°C with the NO donor SNP (12.5 lM), the sGC inhibitor 1H- [1, 2, 4] oxadiazolo-[4,3-a]quinoxalin-1-one (ODQ) (50 lM), the membrane-permeable analog of cGMP 8-bromo guanosine-3 0 ,5 0 -cyclic monophosphate (8-Br-cGMP) (100 lM), and the PKG inhibitor 8-bromo guanosine-3 0 ,5 0 -cyclic monophosphorothioate Rp-isomer (Rp-cGMPS; Calbiochem-Novabiochem Corporation, San Diego, CA, USA) (100 lM). Platelets were then sedimented by centrifugation at 2,000 9 g for 5 min and solubilized directly in lysis buffer (1% SDS, 0.1% Triton X-100, 10 mM Tris-HCl, 10% b-mercaptoethanol, 0.002% bromophenol blue, pH 7.4) supplemented with a protease inhibitor cocktail set III [100 mM 4-(2-aminoethyl)benzenesulphonyl fluoride, 80 mM aprotinin, 5 mM bestatin, 1.5 mM E-64, 2 mM leupeptin, 1 mM pepstatin; Calbiochem-Novabiochem Corporation, San Diego, CA, USA]. After centrifugation at 13,000 9 g for 15 min, aliquots containing 30 lg of proteins were subjected to sodium dodecylsulfate-polyacrylamide gel electrophoresis (12% polyacrylamide), transferred to polyvinylidene difluoride filter membrane (Immobilon P, Millipore, Bedford, MA, USA) and probed with: a rabbit polyclonal antibody (diluted 1:100 in TBS 19, non-fat dry milk 3% with 0. After an overnight incubation, the membrane was washed with PBS-Tween 0.1% and subjected for 1 h to the following: peroxidase-conjugated antibody (diluted 1:1,000 in PBS-Tween with blocker non-fat dry milk 5%, Bio-rad Laboratories); anti-chicken c-globulin (Calbiochem-Novabiochem Corporation; catalog no. 345877); anti-sheep IgG (Upstate, D.B.A.; catalog no. 12-342); anti-mouse or anti-rabbit IgG (donkey; Amersham International; catalog no. NA931V and NA934V). The membrane was washed again with PBS-Tween, and proteins were visualized by the SuperSignal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL, USA). Molecular weight standards were used in all gels.
Statistical analysis
Continuous variables, presented as means and standard error of the mean (SEM), were compared, after a normalized distribution was assured, by Student's t test for equality of means and by repeated-measures one-way ANOVA followed by Bonferroni and Tukey multiple comparison test. Categorical variables, presented as counts and percentages, were compared in cross tabulations tables by means of the Pearson chi-square test and likelihood ratio. All statistical analysis was performed with the program package STATA Ò v 8.0. The level of significance was taken as two-tailed p = 0.05.
Results
Clinical and biochemical features of healthy subjects, UA and AMI patients are reported in Table 1 . Platelet count (910 3 /mm 3 ) in patients with UA (278 ± 48) was significantly lower compared to both patients with AMI (372 ± 62, p \ 0.02) and healthy subjects (342 ± 128, p \ 0.02).
Serum markers of inflammation and thrombophilic status
Serum markers of platelet activation (sP-selectin), inflammation (TNF-a and erythrocyte sedimentation rate), thrombotic state (fibrinogen) and plaque disruption (HsCRP) were significantly higher in both UA and AMI patients compared to healthy controls (Table 1) .
Basal platelet cGMP (pmol/10 10 platelets) was higher in both UA (1,097 ± 111; p \ 0.001) and AMI patients (1,122 ± 77; p \ 0.001) compared to healthy subjects (497 ± 80) (Fig. 1) .
Following exposure to SNP, the cGMP increase was greater in UA patients (4,396 ± 316 pmol/10 10 platelets; p \ 0.0001) than in AMI patients (2,418 ± 126 pmol/10 10 platelets; p \ 0.001) and healthy subjects (2,458 ± 414 pmol/10 10 platelets; p \ 0.001) (Fig. 1) . The SNP effect was instead similar in AMI patients and healthy controls (Fig. 1) .
The basal expression of the sGC subunits a1 and b1 by western blot analysis of platelets homogenates was similar in the three study groups (Fig. 2 ).
Akt and eNOS phosphorylation
The NO signaling pathway activation involves the eNOS phosphorylation by the protein kinase Akt1/PKBa, which
is in turn previously was activated via PI3K-mediated signaling. The Akt1/PKBa phosphorylation at Ser 473 ( Fig. 3 ) and the eNOS phosphorylation at Ser 1177 (Fig. 4 ) were significantly increased in platelets from UA and AMI patients, when compared to healthy subjects.
VASP phosphorylation at serine 239
Phospho-VASP(Ser 239 ), a marker of PKG activation, was not detectable in platelets from healthy subjects. VASP phosphorylation was instead clearly present in UA and, even more, in AMI platelets (Fig. 5 ). The incubation with Fig. 2 Expression of sGC subunits a 1 (73-82 kDa) and b 1 (70-72 kDa) in healthy subjects (CTRL), UA patients and AMI patients. Western blot analysis was performed as described under the ''Materials and methods''. Top the figure is representative of the experiments performed on each healthy subject or patient. Bottom the protein bands obtained from 14 healthy subjects (CTRL), 10 UA patients and 14 AMI patients have been quantitated densitometrically. Values, expressed as arbitrary units, are represented as means ± SEM SNP and 8-bromo-cGMP induced VASP phosphorylation in control and UA platelets to levels quite superimposable to those basally observed in AMI platelets. AMI platelets were insensitive to SNP and 8-bromo-cGMP incubation (Fig. 5) . In healthy and UA platelets ODQ reverted the SNP-induced effect, and Rp-8-Br-cGMPS reverted the 8-bromo-cGMP-induced effect, suggesting, respectively, a sGC and PKG mediation. The two inhibitors, on the contrary, did not decrease the phospho-VASP levels in AMI platelets, already maximally expressed under basal conditions (Fig. 5) .
Discussion
The main finding of the present study is that platelets from patients with acute coronary syndromes not on therapy with nitrates, salicylates (or derivatives), statins, or any other antiplatelet and anticoagulant drug, exhibited a divergent behavior from platelets of healthy subjects. In addition, platelets from patients presenting with UA showed some different characteristics from those collected from AMI patients.
In comparison with healthy subjects, UA and AMI patients exhibited higher levels of serum sP-selectin, a sensitive marker of in vivo platelet activation and endothelial activation [12, 15] . This protein plays a key role at sites of tissue injury and inflammation initiating the attachment of leukocytes circulating in the blood to platelets, endothelial cells, and other leukocytes [31] . The basal level of cGMP was significantly increased in both types of patients versus control subjects, but the administration of SNP caused a higher increase in UA patients than in AMI patients (which exhibited a response similar to controls). This effect was not attributable to a different expression of sGC isoforms, since their Western blot analysis showed a comparable expression of the sGC subunits a1 and b1 in all three study groups.
sGC activity, in several cell types, is modulated by NO via a signaling pathway involving NOS activation by a cascade of kinases, such as PI3K and Akt/PKB [2] . PI3K promotes Akt activation during platelet stimulation [18, 29] , and two different isoforms of Akt, Akt1/PKBa and Akt2/PKBb, have been found to play a role in platelet activation [3] . Once phosphorylated, Akt is known to phosphorylate and activate, in its turn, other proteins, including eNOS [9] . Several platelet agonists may sequentially activate PI3K, Akt, and eNOS, and the synthesis of NO [26] subsequently stimulates sGC and causes an increase of intracellular cGMP. In the present study this mechanism seems to be involved in both UA and AMI platelets, as the major downstream effector of PI3K (Akt) and of Akt (eNOS) exhibited a significant increase in basal phosphorylation compared to healthy subjects. Moreover, AMI patients showed an increase of eNOS phosphorylation much higher than UA patients. Viewed in parallel with the lower increase of cGMP after SNP stimulation, this is an indirect evidence that eNOS, although more activated, is not able to bypass the resistance of sGC to NO. The assessment of NO levels directly produced by the platelets is unfortunately affected by the impossibility to maintain these cells in culture for the incubation time (at least 12-24 h) needed to measure detectable amounts of nitrite, the stable derivative of NO. Furthermore, in an ex vivo study like the present, administering NO/NOS inhibitors in vivo to patients and healthy controls monitoring the effect on basal platelet cGMP is not possible. For these reasons we looked for Akt and eNOS phosphorylation in patients with an acute coronary syndrome, in order to find signs of altered functions of the NO/cGMP signaling pathway.
Although it is generally assumed that NO and cGMP, via PKG, play inhibitory roles in platelet activation, recent evidences suggest that low concentrations of endogenously synthesized NO and cGMP may, on the opposite, promote platelet secretion and aggregation [6] [7] [8] . Furthermore, it has been recently observed that PKG may play an important stimulatory role. Platelets from PKG knockout mice and human platelets treated with PKG inhibitors showed reduced platelet aggregation in response to low-dose agonists, including thrombin, thromboxane B 2 , von Willebrand factor and collagen [17] . VASP (46-50 kDa) has been identified as a substrate for both PKG and cAMP-dependent protein kinase (PKA). This phosphoprotein is preferentially phosphorylated at Ser 239 by PKG and at Ser 157 by PKA: the level of phospho-VASP(Ser 239 ) is a reliable marker of PKG activation [16, 23] . The present study, showing significantly higher levels of phosphorylated VASP in platelets from UA and AMI patients compared to those collected from healthy controls, supports the hypothesis of an activated NO/cGMP pathway in patients with acute coronary syndromes. We suggest that the higher degree of eNOS activation causes a relatively stable modification in sGC, leading to its minor response to NO (clearly evident in AMI patients).
One of the triggers of this phenomenon may be the proinflammatory cytokine TNF-a, as its circulating levels were significantly increased in both UA and AMI patients [8, 21] . Indeed, TNF-a is known to promote platelet aggregation in patients with heart failure [24] , and has recently been shown to stimulate eNOS phosphorylation via the PI3K/Akt signal transduction pathway [1, 7, 13] .
Previous literature has reported that in patients with acute coronary syndromes platelets become resistant to NO, showing a decreased responsiveness to the antiaggregatory effects of NO donors [4] . Interestingly, our investigation showed that the ability of the NO donor SNP to further increase cGMP was fully maintained in platelets from UA patients, while it was strongly impaired in AMI platelets, suggesting different platelet reactivities in these two groups. The resistance of AMI platelets was exhibited not only at the sGC step, but also at the level of PKGmediated VASP phosphorylation: both SNP and 8-BrcGMP were unable to increase VASP phosphorylation levels. Such finding could be consequence of the already high and stable basal level of VASP phosphorylation in AMI platelets not revertible either by the sGC inhibitor ODQ or the PKG inhibitor Rp-8-Br-cGMPS. The onset of NO resistance observed in patients with acute coronary syndromes has been attributed to an impairment of sGC and/or to the scavenging of NO by the superoxide anion radical [10] : the precise molecular modifications responsible for the desensitization of the NO/cGMP pathway remain hitherto not identified.
Conclusion
The present data investigating the NO/cGMP signaling pathway in basal conditions and after stimulation with SNP in platelets from patients with acute coronary syndrome suggest that this signaling pathway is more complex than the one previously hypothesized. In particular, platelets collected from UA and AMI patients showed clear-cut differences, with platelets from AMI patients being more resistant to SNP effects.
Platelet hyperaggregability combined with hyporesponsiveness to exogenous NO donors in AMI patients may reflect an impaired physiological response to endogenous NO, and could contribute to the increased risk of ischemic events. Indeed Willoughby et al. [33] showed that a reduced platelet response to NO administration in the first hours from the onset of symptoms is associated with a worse prognosis in UA patients, as to relapsed incidence and increased mortality. Indeed, in AMI patients, there is lack of evidence supporting nitrovasodilators efficacy in inhibiting platelet activation, and these drugs have not proved beneficial in terms of mortality decrease [5, 6, 22] .
